Best Practice & Research Clinical Haematology最新文献

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential CAR-T细胞治疗多发性骨髓瘤：现状和未来潜力的最新进展

IF 2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-10-04 DOI: 10.1016/j.beha.2025.101659

Prateek Pophali , Jacalyn Rosenblatt , David Avigan

{"title":"CAR-T cell therapy for multiple myeloma: An update on the current state and future potential","authors":"Prateek Pophali , Jacalyn Rosenblatt , David Avigan","doi":"10.1016/j.beha.2025.101659","DOIUrl":"10.1016/j.beha.2025.101659","url":null,"abstract":"<div><div>The field of multiple myeloma (MM) has seen significant therapeutic advances over the last decade including the recent advent of Chimeric Antigen Receptor T cell (CAR-T) therapy. Currently there are two FDA approved CAR-T products for MM, both targeting B cell maturation antigen (BCMA). These agents have demonstrated striking therapeutic efficacy in patients with advanced disease and are now also approved in earlier relapse. CAR-T therapy is associated with unique toxicities including cytokine release syndrome, neurotoxicity, hypogammaglobulinemia, risk of infections and cytopenias. While response rates are dramatic, most patients ultimately experience disease progression due to therapeutic resistance potentially arising from lack of persistence and exhaustion of CAR-T cells, emergence of antigen negative variants, and the immunosuppressive tumor microenvironment. Significant efforts in the field are dedicated towards improving the efficacy and mitigating the toxicity of CAR-T cell therapy. In this publication, we review the approved and investigational CAR-T models for MM.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 4","pages":"Article 101659"},"PeriodicalIF":2.0,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use 恶性血液病肿瘤疫苗：临床使用的合理性和证据的系统回顾

IF 2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-08-20 DOI: 10.1016/j.beha.2025.101650

T. Anders Olsen , Kevin J. Barnum , David Avigan , Jacalyn Rosenblatt

{"title":"Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use","authors":"T. Anders Olsen , Kevin J. Barnum , David Avigan , Jacalyn Rosenblatt","doi":"10.1016/j.beha.2025.101650","DOIUrl":"10.1016/j.beha.2025.101650","url":null,"abstract":"<div><div>Immunotherapy, including immune checkpoint blockade, CART cells and bispecific antibodies have resulted in dramatic improvements in outcomes for patients with hematological malignancies, demonstrating the unique potency of the immune system in targeting malignant cells. The development of cancer vaccines aims to evoke an activated effector cell population and a memory response to provide long term immune surveillance to protect from relapse. Developing a potent cancer vaccine relies on identifying appropriate antigen targets, enhancing antigen presentation, and overcoming the immune suppressive milieu of the micro-environment. Critical advances include the identification of neoantigens as targets for high affinity T cells, multi-antigenic targets via whole-cell or multi-peptide platforms, dendritic cell-based strategies, and adjunct immunoregulatory agents to enhance response. In the present review, we examine the current understanding of immune dysregulation in hematologic malignancies, the rationale for cancer vaccines, and the clinical and immunologic response data available from preclinical and clinical settings.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 3","pages":"Article 101650"},"PeriodicalIF":2.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144902426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bispecific T-cell engager therapy for multiple myeloma 双特异性t细胞接合疗法治疗多发性骨髓瘤

IF 2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-08-05 DOI: 10.1016/j.beha.2025.101649

Diana Cirstea , Benjamin Puliafito , Bridget E. Kim , Matt Lei , Noopur Raje

引用次数: 0

Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025] “精确免疫调节：理解和利用细胞因子途径来治疗和预防免疫相关不良事件（irAEs）”的勘误表[最佳实践Res临床血血学38 2 2025]

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-07-18 DOI: 10.1016/j.beha.2025.101648

Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds

引用次数: 0

Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception 前体浆细胞疾病：分类、风险分层和早期阻断的新作用

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-07-09 DOI: 10.1016/j.beha.2025.101641

Tarek H. Mouhieddine , Irene M. Ghobrial , Omar Nadeem

引用次数: 0

Immune therapy of haematological cancers 血液学癌症的免疫治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-04 DOI: 10.1016/j.beha.2025.101640

Bin Pan , Robert Peter Gale MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hc), FRSM

引用次数: 0

Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs) 精确免疫调节：理解和利用细胞因子途径治疗和预防免疫相关不良事件（irAEs）

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 DOI: 10.1016/j.beha.2025.101625

Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds

{"title":"Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)","authors":"Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds","doi":"10.1016/j.beha.2025.101625","DOIUrl":"10.1016/j.beha.2025.101625","url":null,"abstract":"<div><div>The utilization of immune checkpoint inhibitors has fundamentally changed both the treatment landscape for a multitude of malignancies as well as our understanding of cancer biology. Despite profound advancements, the utilization of these drugs is often limited by the development of immune-related adverse events (irAEs), characterized by off-target toxicity to healthy tissue secondary to treatment. Currently, irAEs are often treated with high-dose corticosteroids, with additional immunosuppressive agents added for severe or refractory irAEs. Cytokine pathway inhibitors, particularly anti-TNFa and anti-IL-6R antibodies, are commonly used as second-line immunosuppression. The efficacy of blocking these pathways in treating irAEs, as well as their potential impact on anti-tumor response, will be discussed. Additionally, this review will also explore other cytokines implicated in irAE pathophysiology, including interleukin-17 (IL-17), interleukin-23 (IL-23), interleukin-4/13 (IL-4/IL-13) and interleukin-5 (IL-5) which play important roles in the inflammatory cascades underlying specific irAEs such as colitis, dermatitis, and eosinophilia-related toxicities.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101625"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in NK cell therapy for multiple myeloma NK细胞治疗多发性骨髓瘤的进展

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-28 DOI: 10.1016/j.beha.2025.101639

Najing Liu , Yujin Zeng , Ying Wang , Congyue Wang , Nuoxian Li , Jinge Xu

引用次数: 0

Adoptive cellular therapies in multiple myeloma 多发性骨髓瘤的过继细胞治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-27 DOI: 10.1016/j.beha.2025.101638

David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Evangelos Terpos , Hermann Einsele , Ciprian Tomuleasa

{"title":"Adoptive cellular therapies in multiple myeloma","authors":"David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Evangelos Terpos , Hermann Einsele , Ciprian Tomuleasa","doi":"10.1016/j.beha.2025.101638","DOIUrl":"10.1016/j.beha.2025.101638","url":null,"abstract":"<div><div>Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved each year. Chimeric antigen receptor (CAR) therapies are an advanced form of immunotherapy that engineer T cells to recognize and destroy cancer cells. In recent years, adoptive cellular therapies have been successfully used to treat relapsed or refractory patients. Now, growing evidence supports their effectiveness when used earlier in treatment, even as an alternative to autologous hematopoietic stem cell transplantation. Ongoing research is expanding CAR therapy to solid tumors and enhancing safety and efficacy through innovative designs and combination strategies. In this paper, we aim to highlight the brief history and the latest advancements in CAR T-cell and NK-cell therapies for plasma cell myeloma.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 3","pages":"Article 101638"},"PeriodicalIF":2.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adoptive cellular therapies in non-Hodgkin lymphomas 非霍奇金淋巴瘤的过继细胞治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-22 DOI: 10.1016/j.beha.2025.101637

David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Anca Colita , Nazar Shokun , Tetiana Skrypets , Hermann Einsele , Massimo Federico , Ciprian Tomuleasa

{"title":"Adoptive cellular therapies in non-Hodgkin lymphomas","authors":"David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Anca Colita , Nazar Shokun , Tetiana Skrypets , Hermann Einsele , Massimo Federico , Ciprian Tomuleasa","doi":"10.1016/j.beha.2025.101637","DOIUrl":"10.1016/j.beha.2025.101637","url":null,"abstract":"<div><div>Lymphomas are a group of malignant proliferations of B, T or NK-lymphoid cells at different stages of maturation. While they primarily occur in lymph nodes or lymphatic tissues, they can also involve bone marrow, blood, or other organs. Despite advances in treatment, many patients experience relapse, or develop refractory disease, prompting the development of new therapies. One of the most promising innovations is represented by chimeric antigen receptors (CAR) T-cell therapy, that works by genetically modifying a patient's T lymphocytes to better target and kill their cancer cells. Currently, all FDA-approved CAR T-cell therapies target CD19 (a surface protein expressed on B lymphocytes), however, ongoing research includes CAR-Ts that address novel targets or target multiple antigens. This study aims to provide a comprehensive overview on the clinical use and therapeutic efficacy of both approved and emerging CAR-Ts in the treatment of lymphoma.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 3","pages":"Article 101637"},"PeriodicalIF":2.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144189302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0